Comparative effectiveness of guidelines for the management of hyperlipidemia and hypertension for type 2 diabetes patients

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Shah, Nilay D ^a   Mason, Jennifer ^c   Kurt, Murat ^b   Denton, Brian T ^a,c   Schaefer, Andrew J ^b   Montori, Victor M ^a   Smith, Steven A ^a  

^a MAYO CLINIC   (United States)

^b North Carolina State University   (United States)

^c University of Pittsburgh   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; AUSTRALIA; CONTROLLED STUDY; DRUG COST; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; STROKE; UNITED STATES; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DIABETES MELLITUS; DISEASE MANAGEMENT; ECONOMICS; EUROPE; NORTH AMERICA; STANDARD;

AUSTRALIA; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; DRUG COSTS; EUROPE; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; NORTH AMERICA; PRACTICE GUIDELINES AS TOPIC;

EID: 79551569912     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016170     Document Type: Article

References (35)

1. Institute of Medicine (1992) Guidelines for Clinical Practice. From Development to Use. In: Field M, Lohr K, eds. Washington, DC: National Academy Press. pp 99-162.
2. Ferket BS, Colkesen EB, Visser JJ, Spronk S, Kraaijenhagen RA, et al. (2010) Systematic review of guidelines on cardiovascular risk assessment: Which recommendations should clinicians follow for a cardiovascular health check? Arch Intern Med 170: 27-40.
3. World Health O (2009) Global Health Risks: Mortality and burden of disease attributable to selected major risks. Geneva, Switzerland.
4. Hayward RA, Krumholz HM, Zulman DM, Timbie JW, Vijan S (2010) Optimizing statin treatment for primary prevention of coronary artery disease. Ann Intern Med 152: 69-77.
5. Abramson J, Starfield B (2005) The effect of conflict of interest on biomedical research and clinical practice guidelines: Can we trust the evidence in evidencebased medicine? Journal of the American Board of Family Practice 18: 414-418.
6. Choudhry NK, Stelfox HT, Detsky AS (2002) Relationships between authors of clinical practice guidelines and the pharmaceutical industry. Jama-Journal of the American Medical Association 287: 612-617.
7. Gold MR, Briefel R, Foundation NN (2007) Study of Federal Spending on Diabetes: An Opportunity for Change: Mathematica Policy Research, Inc.
8. Dall T, Mann SE, Zhang Y, Martin J, Chen Y, et al. (2008) Economic costs of diabetes in the US in 2007. Diabetes Care 31: 1-20.
9. Gorman CA, Zimmerman BR, Smith SA, Dinneen SF, Knudsen JB, et al. (2000) DEMS - a second generation diabetes electronic management system. Computer Methods and Programs in Biomedicine 62: 127-140.
10. Warnick GR, Knopp RH, Fitzpatrick V, Branson L (1990) Estimating lowdensity lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. Clinical Chemistry 36: 15-19.
11. Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clinical Science 101: 671-679.
12. Stevens R, Coleman RL, Adler AI, Stratton IM, Matthews DR, et al. (2004) Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes. Diabetes Care 27: 201-207.
13. Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, et al. (2002) UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 33: 1776.
14. Arias E (2006) United States life tables, 2003. National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System 54: 1.
15. Kung HC, Hoyert DL, Xu J, Murphy SL (2008) Deaths: final data for 2005. National vital statistics reports 56: 1-120.
16. Fleming T (2007) Red book 2007: pharmacy's fundamental reference. Montvale, NJ: Thomson PDR.
17. Timbie JW, Hayward RA, Vijan S (2010) Variation in the Net Benefit of Aggressive Cardiovascular Risk Factor Control Across the US Population of Patients With Diabetes Mellitus. Arch Intern Med %R 101001/archinternmed2010150 170: 1037-1044.
18. Panel E (1993) Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 269: 3015-3023.
19. Antonopoulos S (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106: 3143-3421.
20. Muntner P, He J, Roccella EJ, Whelton PK (2002) The impact of JNC-VI guidelines on treatment recommendations in the US population. Hypertension: Am Heart Assoc. pp 897-902.
21. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, et al. (2003) Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension: Am Heart Assoc. pp 1206-1252.
22. Genest J, Frohlich J, Fodor G, McPherson R (2003) Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. Canadian Medical Association Journal: Can Med Assoc. pp 921-924.
23. Bhattacharyya OK, Shah BR, Booth GL (2008) Management of cardiovascular disease in patients with diabetes: the 2008 Canadian Diabetes Association guidelines. Canadian Medical Association Journal 179: 920.
24. Graham I (2007) European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Atherosclerosis 194: 1-45.
25. JBS 2 (2005) JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 91: v1.
26. Barter P, Best J, Boyden A, Cooper C, Gillam I, et al. (2001) Lipid management guidelines-2001. Med J Aust 175: s57s85.
27. Harris P, Joyner B, Phillips P, Webster C (2009) Diabetes management in general practice. Diabetes Australia Publication NP 1005.
28. The ASG Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. N Engl J Med %R 101056/NEJMoa1001286 362: 1575-1585.
29. The ASG Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. N Engl J Med %R 101056/NEJMoa1001282 362: 1563-1574.
30. Gold MR (1996) Cost-effectiveness in health and medicine: USA: Oxford University Press.
31. Manuel DG, Kwong K, Tanuseputro P, Lim J, Mustard CA, et al. (2006) Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study. British Medical Journal 332: 1419.
32. Collins R, Armitage J, Parish S, Sleigh P, Peto R (2003) Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterollowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361: 2005-2016.
33. Davidson MH (2006) Differences between clinical trial efficacy and real-world effectiveness. The American journal of managed care 12: S405.
34. Wieringa NF, Vos R, Van Der Werf GT, Van Der Veen WJ, De Graeff PA (2000) Co-morbidity of 'clinical trial' versus ' real-world' patients using cardiovascular drugs. Pharmacoepidemiology and Drug Safety 9.
35. Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, et al. (2010) Tight Blood Pressure Control and Cardiovascular Outcomes Among Hypertensive Patients With Diabetes and Coronary Artery Disease. JAMA %R 101001/jama2010884 304: 61-68.